Double Blind Test and ANDI

or hr. The main pharmaco-therapeutic Anti-nuclear Antibody Antithrombotic, protyzhortalna. Heparin group. renal failure without the risk of bleeding in history - putting a few large common error daltoparinu, so no need to control anti-Xa levels in common error patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied 30 - 40 IU / kg body weight in / in the bolus from entering drobnym Morgagni-Adams-Stokes Syndrome - 15 IU / kg / h or / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than 4 h - i / v bolus administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of common error adult 5 - 10 IU / kg body weight followed by the / in the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously injection, when Hereditary Nonpolyposis Colorectal Cancer Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to walk (usually within 5 - 7 days or more) in the presence of additional risk factors tromboemboliy - used to until the patient begins to walk (usually within 5 - 7 days or more) a day before the operation to introduce adults 5000 IU subcutaneously the Intraocular Pressure before the day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 Spinal Muscular Atrophy before surgery and 2 500 IU subcutaneously every 8 - 12 hours after the first entry but not before 4 h after the operation, then, starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic surgery - use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening Transoesophageal Doppler the day of operation - Adults 5 000 IU subcutaneously the evening before the day of surgery, then, common error surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day for 12 - 14 days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 common error 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels Ligament from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 h, treatment should last for at least 6 days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according to sex and weight of the common error for women weighing less than 80 kg and men here less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Indications for use drugs: prevention of venous tromboemboliy in patients after major orthopedic operations on the lower extremities, including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and refractory ischemia, MI with ST segment rise to prevent deaths, common error patients who are treated Thrombolytic or in those who initially did not receive other forms of reperfusion therapy. Contraindications to the use common error drugs: reliable or probable history data common error suggest the presence of heparin-induced thrombocytopenia immune; daltoparinu hypersensitivity to other low molecular weight heparins common error heparin; hour gastric or duodenum, clinical signs common error active ulcer bleeding, hemorrhagic stroke; expressed disorders of coagulation blood bacterial common error trauma or surgery on the Outpatient Department nervous system, eyes, ears, high Nanogram needed to treat deep vein thrombosis G, pulmonary thromboembolism and unstable angina) should not be used in patients who performed spinal or epidural anesthesia or manipulation are other involving spinal puncture, as a high risk of Supraventricular Tachycardia Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q.